Literature DB >> 30911113

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

Billy Michael Chelliah Jebaraj1, Eugen Tausch1, Dan A Landau2,3,4, Jasmin Bahlo5, Sandra Robrecht5, Amaro N Taylor-Weiner6, Johannes Bloehdorn1, Annika Scheffold1, Daniel Mertens1,7, Sebastian Böttcher8,9, Michael Kneba8, Ulrich Jäger10, Thorsten Zenz1,11, Michael K Wenger12, Guenter Fingerle-Rowson12, Clemens Wendtner13, Anna-Maria Fink5, Catherine J Wu6, Barbara Eichhorst5, Kirsten Fischer5, Michael Hallek5, Hartmut Döhner1, Stephan Stilgenbauer14.   

Abstract

Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In the present study, we performed a comprehensive analysis of telomere length associations in the well characterized CLL8 trial (n = 620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n = 293). Absolute telomere length was analyzed using quantitative-PCR. Apart from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones. Thus, telomere shortening may precede acquisition of the high-risk aberrations, contributing to disease evolution. In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.

Entities:  

Mesh:

Year:  2019        PMID: 30911113      PMCID: PMC6737251          DOI: 10.1038/s41375-019-0446-4

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Authors:  Stephan Stilgenbauer; Andrea Schnaiter; Peter Paschka; Thorsten Zenz; Marianna Rossi; Konstanze Döhner; Andreas Bühler; Sebastian Böttcher; Matthias Ritgen; Michael Kneba; Dirk Winkler; Eugen Tausch; Patrick Hoth; Jennifer Edelmann; Daniel Mertens; Lars Bullinger; Manuela Bergmann; Sabrina Kless; Silja Mack; Ulrich Jäger; Nancy Patten; Lin Wu; Michael K Wenger; Günter Fingerle-Rowson; Peter Lichter; Mario Cazzola; Clemens M Wendtner; Anna M Fink; Kirsten Fischer; Raymonde Busch; Michael Hallek; Hartmut Döhner
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

Review 3.  The role of telomere biology in cancer.

Authors:  Lifeng Xu; Shang Li; Bradley A Stohr
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

4.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

Review 5.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

6.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

Authors:  Jennifer Edelmann; Karlheinz Holzmann; Florian Miller; Dirk Winkler; Andreas Bühler; Thorsten Zenz; Lars Bullinger; Michael W M Kühn; Andreas Gerhardinger; Johannes Bloehdorn; Ina Radtke; Xiaoping Su; Jing Ma; Stanley Pounds; Michael Hallek; Peter Lichter; Jan Korbel; Raymonde Busch; Daniel Mertens; James R Downing; Stephan Stilgenbauer; Hartmut Döhner
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

Review 7.  Prognostic markers and standard management of chronic lymphocytic leukemia.

Authors:  Stephan Stilgenbauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

8.  Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia.

Authors:  Alexander Röth; Dirk de Beer; Holger Nückel; Ludger Sellmann; Ulrich Dührsen; Jan Dürig; Gabriela M Baerlocher
Journal:  Br J Haematol       Date:  2008-08-28       Impact factor: 6.998

Review 9.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

10.  Longer telomeres are associated with cancer risk in MMR-proficient hereditary non-polyposis colorectal cancer.

Authors:  Nuria Seguí; Elisabet Guinó; Marta Pineda; Matilde Navarro; Fernando Bellido; Conxi Lázaro; Ignacio Blanco; Victor Moreno; Gabriel Capellá; Laura Valle
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more
  8 in total

1.  CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.

Authors:  Erika Tissino; Federico Pozzo; Dania Benedetti; Chiara Caldana; Tamara Bittolo; Francesca Maria Rossi; Riccardo Bomben; Paola Nanni; Hillarj Chivilò; Ilaria Cattarossi; Eva Zaina; Kevin Norris; Jerry Polesel; Massimo Gentile; Giovanni Tripepi; Riccardo Moia; Enrico Santinelli; Idanna Innocenti; Jacopo Olivieri; Giovanni D'Arena; Luca Laurenti; Francesco Zaja; Gabriele Pozzato; Annalisa Chiarenza; Francesco Di Raimondo; Davide Rossi; Chris Pepper; Tanja Nicole Hartmann; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei; Antonella Zucchetto
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

Review 2.  Telomere Length and Hematological Disorders: A Review.

Authors:  Beatriz Maria Dias Nogueira; Caio Bezerra Machado; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

3.  The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Authors:  Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Silvia Imbergamo; Edoardo Scomazzon; Stefano Pravato; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Maurizio Nanni; Ilaria Del Giudice; Monica Facco; Anna Guarini; Gianpietro Semenzato; Robin Foà; Antonio Cuneo; Livio Trentin
Journal:  Br J Cancer       Date:  2019-06-18       Impact factor: 7.640

Review 4.  Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability.

Authors:  Kristyna Zavacka; Karla Plevova
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

5.  Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.

Authors:  Panagiotis Baliakas; Blanca Espinet; Clemens Mellink; Marie Jarosova; Anastasia Athanasiadou; Paolo Ghia; Arnon P Kater; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Hemasphere       Date:  2022-03-25

6.  Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.

Authors:  Andrea G S Pepper; Antonella Zucchetto; Kevin Norris; Erika Tissino; Jerry Polesel; Zarni Soe; David Allsup; Anna Hockaday; Pei Loo Ow; Peter Hillmen; Andrew Rawstron; Daniel Catovsky; Pietro Bulian; Riccardo Bomben; Duncan M Baird; Christopher D Fegan; Valter Gattei; Chris Pepper
Journal:  Leukemia       Date:  2021-06-19       Impact factor: 11.528

7.  Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.

Authors:  Helena Olbertova; Karla Plevova; Sarka Pavlova; Jitka Malcikova; Jana Kotaskova; Kamila Stranska; Michaela Spunarova; Martin Trbusek; Veronika Navrkalova; Barbara Dvorackova; Nikola Tom; Karol Pal; Marie Jarosova; Yvona Brychtova; Anna Panovska; Michael Doubek; Sarka Pospisilova
Journal:  BMC Cancer       Date:  2022-02-03       Impact factor: 4.430

8.  The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.

Authors:  Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Stefano Pravato; Leila Romano Gargarella; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Mauro Nanni; Monica Facco; Francesco Piazza; Anna Guarini; Robin Foà; Gianpietro Semenzato; Antonio Cuneo; Livio Trentin
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.